EN
DE
Home
About us
Biofronteras Expertise
Management and supervisory board
Product Pipeline
Clinical trials
Products
Product Portfolio
Investors & Media
Key stock information
Financial reports
Financial announcements
Shareholder structure
Corporate calendar
Corporate governance
Annual general meeting
Presentations & contact
Career
Careers
Contact
Biofrontera
Investors & Media
Financial announcements
Corporate News
Corporate News
10/16/2024 11:05
PTA-News: Biofrontera AG: Biofrontera announces agreement with Galenica AB for the promotion and distribution of Ovixan® in the United Kingdom
09/30/2024 15:05
PTA-News: Biofrontera AG: BIOFRONTERA REPORTS RESULTS FOR THE FIRST HALF OF 2024
08/30/2024 14:35
PTA-News: Biofrontera AG: Successful Annual General Meeting with broad approval and new Supervisory Board members
08/14/2024 10:00
PTA-News: Biofrontera AG: Biofrontera announces agreement with LEO Pharma Germany for the promotion of Advantan® and Skinoren®
07/01/2024 10:55
PTA-News: Biofrontera AG: Biofrontera hosted CME-Certified Training "Photodynamic Therapy (PDT) at the Cutting Edge" in Berlin
06/13/2024 16:30
PTA-News: Biofrontera AG: Biofrontera AG announces the registration of the capital increase
05/31/2024 09:05
PTA-News: Biofrontera AG: BIOFRONTERA REPORTS RESULTS FOR THE FIRST QUARTER OF 2024
05/14/2024 10:30
PTA-News: Biofrontera AG: Biofrontera strategically on course for growth; Realignment of the Supervisory Board
05/08/2024 17:00
PTA-News: Biofrontera AG: Biofrontera executes capital reduction and capital increase
04/30/2024 10:15
PTA-News: Biofrontera AG: BIOFRONTERA REPORTS RESULTS FOR THE FINANCIAL YEAR 2023
02/20/2024 14:15
PTA-News: Biofrontera AG: Biofrontera transfers clinical research to the U.S.
02/19/2024 11:45
PTA-News: Biofrontera AG: Biofrontera and GME enter into a cooperation to promote the MultiLite® daylight lamp for PDT treatment
02/05/2024 10:15
PTA-News: Biofrontera AG: Ameluz® obtains approval extension for use with artificial daylight in the EU and the UK
01/24/2024 11:20
PTA-News: Biofrontera AG: EMA approves an optimized formulation of Ameluz®
01/08/2024 15:38
PTA-News: Biofrontera AG: EMA recommends Ameluz® label extension for actinic keratosis treatment with artificial daylight
Corporate News archive
2023
2023
11/28/2023 09:30
PTA-News: Biofrontera AG: Biofrontera Reports Business Performance in the Third Quarter and First Nine Months of 2023
08/31/2023 10:00
PTA-News: Biofrontera AG: BIOFRONTERA PRESENTS THE RESULTS OF THE FIRST HALF OF 2023
07/10/2023 13:50
PTA-News: Biofrontera AG: Biofrontera Settles with its Major Shareholders
07/05/2023 11:25
PTA-News: Biofrontera AG: Biofrontera launches novel BELIXOS® ACTIVE CARE
05/31/2023 11:30
PTA-News: Biofrontera AG: Biofrontera reports results for the first quarter of 2023
05/29/2023 12:05
PTA-News: Biofrontera AG: First quarter conference call to be held on May 31, 2023
05/17/2023 09:20
PTA-News: Biofrontera AG: Biofrontera completes patient recruitment of Ameluz® Phase I trial
04/27/2023 23:20
PTA-News: Biofrontera AG: BIOFRONTERA REPORTS RESULTS FOR THE FISCAL YEAR 2022
01/18/2023 11:50
PTA-News: Biofrontera AG: Start of Phase 3 Clinical Trial in the US for the Treatment of Actinic Keratosis on the Extremities, Neck and Trunk
01/12/2023 11:30
PTA-News: Biofrontera AG: Biofrontera receives notice of allowance for US patent on innovative photodynamic treatment protocol
01/06/2023 08:25
PTA-News: Biofrontera AG: Court Rules 2021 Executive Board and Supervisory Board Resolutions Concerning IPO of Biofrontera Inc. To Be Unlawful
2022
2022
12/19/2022 14:05
PTA-News: Biofrontera AG: Commercial launch of Ameluz® in Finland
12/08/2022 13:55
PTA-News: Biofrontera AG: Biofrontera establishes UK subsidiary to strengthen its sales activities in the country
11/23/2022 15:00
PTA-News: Biofrontera AG: Biofrontera reports on business development in the third quarter and the first nine months of 2022
11/16/2022 12:35
PTA-News: Biofrontera AG: Biofrontera AG strengthens international marketing and sales activities
10/26/2022 08:40
PTA-News: Biofrontera AG: Subscription offer for up to 7,089,673 new shares begins on October 28, 2022
09/06/2022 09:50
PTA-News: Biofrontera AG: Biofrontera AG obtains notice of allowance for U.S. patent on nanoemulsion formulation
08/25/2022 10:30
PTA-News: Biofrontera AG: Annual General Meeting of Biofrontera AG appoints Prof. Dr. Karin Lergenmüller as a member of the Supervisory Board
08/19/2022 19:50
PTA-News: Biofrontera AG: Biofrontera extends appointment of Management Board member Paul Böckmann
08/18/2022 21:20
PTA-News: Biofrontera AG: Biofrontera reports financial results for the six months ended June 30, 2022
08/10/2022 14:00
PTA-News: Biofrontera AG: The request to convene an extraordinary shareholders' meeting by Maruho is not complied with
08/05/2022 11:30
PTA-News: Biofrontera AG: Maruho Deutschland GmbH demands convening of an extraordinary general meeting
08/03/2022 10:30
PTA-News: Biofrontera AG: Employees appeal in own statement to the shareholders not to accept the takeover offer of Deutsche Balaton AG
07/29/2022 21:00
PTA-News: Biofrontera AG: Management Board and Supervisory Board jointly recommend not to accept the takeover offer of Deutsche Balaton AG
07/21/2022 16:25
PTA-News: Biofrontera AG: Biofrontera AG will publish statement on takeover offer by Deutsche Balaton AG shortly
07/13/2022 14:55
PTA-News: Biofrontera AG: Biofrontera obtains notice of allowance for Australian patent on innovative PDT treatment protocol
06/08/2022 14:15
PTA-News: Biofrontera AG: Biofrontera's license partner Louis Widmer receives an extension of its marketing authorization for Ameluz®
05/17/2022 16:20
PTA-News: Biofrontera AG: Biofrontera reports results for the first quarter of 2022
05/13/2022 18:20
PTA-News: Biofrontera AG: First quarter conference call to be held on May 19, 2022
04/30/2022 08:30
PTA-News: Biofrontera AG: Biofrontera reports results for the fiscal year 2021
04/28/2022 11:35
PTA-News: Biofrontera AG: Biofrontera shifts the publication of the Annual Report 2021 to April 29, 2022
04/14/2022 14:20
PTA-News: Biofrontera AG: Biofrontera announces conference call to be held on April 29, 2022 to discuss fiscal year 2021 financial results
04/04/2022 14:35
PTA-News: Biofrontera AG: Governmental price decree for Ameluz® withdrawn in Spain
04/04/2022 12:05
PTA-News: Biofrontera AG: Statement of Biofrontera AG on the open letter of Maruho Deutschland GmbH dated March 31, 2022
03/14/2022 12:30
PTA-News: Biofrontera AG: Biofrontera improves the brand protection of Ameluz®-PDT in the US and strengthens internal quality assurance structures
03/09/2022 22:45
PTA-News: Biofrontera AG: Biofrontera files Form 15F to suspend SEC Reporting Requirements and starts trading Level I ADS program on US OTC market
02/01/2022 14:30
PTA-News: Biofrontera AG: Biofrontera AG announces progress of phase III study for the treatment of sBCC with Ameluz®
2021
2021
12/14/2021 17:15
PTA-News: Biofrontera AG: Biofrontera AG announces results of the elections for the new Supervisory Board
12/13/2021 15:05
PTA-News: Biofrontera AG: Biofrontera enrolls first patient to phase IIb clinical study evaluating Ameluz® / BF-RhodoLED® for acne
12/08/2021 13:25
PTA-News: Biofrontera AG: Biofrontera AG obtains notice of allowance for US patent on PDT-lamp and treatment method
12/06/2021 12:50
PTA-News: Biofrontera AG: Biofrontera enrolls first patient to phase I safety study evaluating photodynamic therapy with three tubes of Ameluz®
12/02/2021 14:40
PTA-News: Biofrontera AG: Biofrontera obtains notice of allowance for US patent on innovative illumination protocol
11/17/2021 23:01
PTA-News: Biofrontera AG: Biofrontera reports financial results for the third quarter and nine months ended September 30, 2021
11/16/2021 14:55
PTA-News: Biofrontera AG: Biofrontera AG announces initiation of clinical studies
11/09/2021 11:40
PTA-News: Biofrontera AG: Conference call to discuss third quarter 2021 financial results to be held on November 18, 2021
11/02/2021 20:10
PTA-News: Biofrontera AG: Biofrontera is setting the path for further expansion in the U.S. with the IPO of its US subsidiary Biofrontera Inc.
10/01/2021 13:40
PTA-News: Biofrontera AG: Biofrontera reports preliminary approximate revenues for the month of September 2021
09/08/2021 18:10
PTA-News: Biofrontera AG: Biofrontera reports preliminary revenue for the month of August 2021
08/19/2021 17:45
PTA-News: Biofrontera AG: Biofrontera reports financial results for the six months ended June 30, 2021
08/12/2021 14:55
PTA-News: Biofrontera AG: Conference call to discuss half-year 2021 financial results to be held on August 20, 2021
08/09/2021 15:00
PTA-News: Biofrontera AG: Biofrontera reports preliminary revenue for the month of July 2021
07/23/2021 10:15
PTA-News: Biofrontera AG: Biofrontera enters into license and supply agreement with Medac for the marketing of Ameluz® in Poland
07/06/2021 16:00
PTA-News: Biofrontera AG: Biofrontera reports preliminary revenue for the month of June 2021
06/22/2021 15:00
PTA-News: Biofrontera AG: Biofrontera provides update on clinical developments
06/07/2021 15:50
PTA-News: Biofrontera AG: Biofrontera reports preliminary revenue for the month of May 2021
05/11/2021 16:35
PTA-News: Biofrontera AG: Biofrontera reports Q1 2021 financial results
05/06/2021 12:50
PTA-News: Biofrontera AG: Biofrontera reports preliminary revenue for the month of April 2021
05/03/2021 15:40
PTA-News: Biofrontera AG: First quarter conference call to be held on May 12, 2021
04/12/2021 19:40
PTA-News: Biofrontera AG: Biofrontera reports results for the 2020 financial year
04/08/2021 16:30
PTA-News: Biofrontera AG: Biofrontera announces preliminary revenue for Q1 2021
03/31/2021 16:00
PTA-News: Biofrontera AG: Biofrontera announces conference call to be held on April 13, 2021 to discuss fiscal year 2020 financial results
03/31/2021 09:40
PTA-News: Biofrontera AG: Biofrontera submits application for FDA approval of new BF-RhodoLED® XL lamp
02/26/2021 15:20
PTA-News: Biofrontera AG: Biofrontera AG announces the closing of the capital raise with gross proceeds of EUR 24.7 million
02/25/2021 15:35
PTA-News: Biofrontera AG: Biofrontera AG announces entry of capital increase into the commercial register
02/24/2021 14:30
PTA-News: Biofrontera AG: Biofrontera submits study report of pharmacokinetics study to FDA
02/02/2021 16:35
PTA-News: Biofrontera AG: Ludwig Lutter appointed new Chief Financial Officer effective March 1, 2021
Corporate News PDF Archive
2020 (Text messages)
2020 (Text messages)
12/07/2020 15:10
PTA-News: Biofrontera AG: Biofrontera enters into a license and supply agreement with Galenica AB for the marketing of Ameluz® in Scandinavia
11/11/2020 13:00
PTA-News: Biofrontera AG: Biofrontera reports third quarter and first nine months 2020 results
11/02/2020 14:00
PTA-News: Biofrontera AG: Biofrontera announces conference call to be held on November 12, 2020 to discuss Q3 2020 financial results
10/14/2020 10:30
PTA-News: Biofrontera AG: Receives reasons from the German Federal Court of Justice for overturning ruling of the Cologne Higher Regional Court
10/08/2020 17:00
PTA-News: Biofrontera AG: Biofrontera AG reports completion of the clinical phase of the pharmacokinetics study
09/22/2020 17:50
PTA-News: Biofrontera AG: German Federal Supreme Court overturns ruling of the Cologne Higher Regional Court
09/09/2020 14:00
PTA-News: Biofrontera AG: Biofrontera AG to participate in two upcoming conferences
08/26/2020 15:40
PTA-News: Biofrontera AG: Biofrontera report results for the first six months of 2020
08/20/2020 19:00
PTA-News: Biofrontera AG: Admission to trading of Biofrontera's 1.00% qualified subordinated mandatory convertible bond 2020/2021
08/19/2020 10:30
PTA-News: Biofrontera AG: Biofrontera announces conference call to be held on August 27, 2020 to discuss half-year 2020 financial results
08/18/2020 11:00
PTA-News: Biofrontera AG: Capital measure oversubscribed: Placement of the 1.00% qualified subordinated mandatory convertible bond 2020/2021
07/23/2020 14:30
PTA-News: Biofrontera AG: Supervisory Board of Biofrontera AG renews Management Board appointment
06/30/2020 14:39
PTA-News: Biofrontera AG: Biofrontera confirms financing need
05/28/2020 17:35
PTA-News: Biofrontera AG: Results of the 2020 Annual General Meeting of Biofrontera AG
05/19/2020 16:15
PTA-News: Biofrontera AG: Biofrontera reports Q1 2020 financial results
05/13/2020 10:00
PTA-News: Biofrontera AG: Biofrontera dismisses case against DUSA Pharmaceuticals, Inc. in California state court
05/12/2020 17:00
PTA-News: Biofrontera AG: Biofrontera announces conference call to be held on May 20, 2020 to discuss first quarter 2020 financial results
2020
2020
20200420_Biofrontera_2019_Earnings_Release_EN_final.pdf
20200417_Q1_2020_prelim_revenue_EN_final.pdf
20200409_YE_con_call_details_EN_final.pdf
20200320_Covid_19_measures_EN_final.pdf
20200310_label_extension_EU-EN_final.pdf
20200219_update_clinical_developments_EN_final.pdf
20200203_EMA_positive_opinion_EN_final.pdf
20200131_restructuring_and_Duenwald_EN_final.pdf
20200114_follow_up_results_periphery_EN_final.pdf
20200106_reorganisation_Inc_EN_final.pdf
2019
2019
190711_PM HV 2019_EN_v2_final.pdf
(235 KB)
190724_PM Ergebnis Erwerbsangebote_EN_v2_final.pdf
(186 KB)
2019.03.25_BFRA corporate update_EN_v4_final.pdf
(276 KB)
2019.03.27_PM_Aufsichtsrat_EN_v2_final.pdf
(184 KB)
2019.04.02_Maruho Angebot Info_EN_v2_final.pdf
(184 KB)
2019.04.15_Q1 2019 prelim revenue_EN_v3_final.pdf
(230 KB)
2019.04.16_con call details_EN_v1_final.pdf
(167 KB)
2019.04.16_Studienergebnisse sekundäre Endpunkte_EN_v3_final.pdf
(235 KB)
2019.04.25_PM Einberufung HV_EN_v2_final.pdf
(203 KB)
2019.04.29_2018 Earnings Release_EN_v8_final.pdf
(234 KB)
2019.05.16_con call details_EN_v1_final.pdf
(180 KB)
2019.05.29_Biofrontera 1Q19 Earnings Release_EN_v8_final.pdf
(256 KB)
2019.06.04_Nominierung AR_EN_v1_final.pdf
(180 KB)
2019.06.12_RJ and JMP Conference_EN_v1_final.pdf
(180 KB)
2019.06.21_PM Angebot Maruho_EN_final.pdf
(186 KB)
2019.07.08_HJ1 2019 prelim revenue_EN_v2_final.pdf
(227 KB)
2019.08.05_PM_corporate update CLS integration_EN_v6_final.pdf
(185 KB)
2019.08.14_con call details_EN_v1_final.pdf
(179 KB)
2019.09.17_Antrag EMA_EN_v3_final.pdf
(183 KB)
2019.09.17_Baader Investment Conference_EN_v1_final.pdf
(176 KB)
2019.10.23_Fall Clinical_DE_v4_final.pdf
(101 KB)
2019.11.06_con call details_EN_final.pdf
(186 KB)
20190108_PM_upscaling batch size_EN_final.pdf
(285 KB)
20190211_PM_Arzneimittel-Schutzrichtlinie_EN_final.pdf
(130 KB)
20190225_PR_SteveAwards_EN_final.pdf
(132 KB)
20190701_PM Angebot Balaton_EN.pdf
(88 KB)
20190827_H1 2019 Earnings Release_EN_v3_final.pdf
(208 KB)
20191122_conference participation_EN_v1_final.pdf
(198 KB)
20191213_CCO BF Inc._EN_final.pdf
(188 KB)
20191220_aoHV Ergebnis_EN_final.pdf
(203 KB)
2018
2018
20181227_PR_Dusa disctrict court_EN_final.pdf
(402 KB)
20181213_PM_unabhängige Prüfung_EN_final.pdf
(144 KB)
20181126_Conference Participation_EN.pdf
(234 KB)
20181116_Q3 2018 Earnings Release_EN_final.pdf
(288 KB)
20181105_PM_Q3 Con Call Datum_EN_final.pdf
(233 KB)
20181015_ Dawson James 2018 Conference_EN_final.pdf
(670 KB)
20181001_PM_Tageslicht CH_EN_final.pdf
(665 KB)
20180926_PM_Patientenrekrutierung_EN_final.pdf
(653 KB)
20180924_PM_Cantor Fitzgerald Healthcare Conference_EN_final.pdf
(665 KB)
20180919_PM_Baader Investment Conference_EN_final.pdf
(667 KB)
20180917_PM_Endless Summer Umsatz_EN_final.pdf
(669 KB)
20180831_Biofrontera 2Q18 Earnings Release_EN_correction.pdf
(730 KB)
20180831_ 2Q18 Earnings Release_EN.pdf
(738 KB)
20180830_PM_HJConCallReminder_EN.pdf
(668 KB)
20180816_PM_VA contract award_EN_final.pdf
(671 KB)
20180815_PM_HJ Con Call Datum_EN_final.pdf
(668 KB)
20180802_PM_Balaton Offer US_EN_final.pdf
(667 KB)
20180730_PM_2nd joint opinion_DBB_EN.pdf
(676 KB)
20180726_PM_Patientenrekrutierung_EN.pdf
(127 KB)
20180713_AGM_EN.pdf
(119 KB)
20180712_DUSA_PM_EN.pdf
(117 KB)
20180710_PM_Biofrontera on Collaboration_EN.pdf
(117 KB)
20180706_FreiwilligePrüfung_EN.pdf
(150 KB)
20180705_PR_HJ1 results_EN.pdf
(119 KB)
20180612_lawsuit_DB_EN.pdf
(107 KB)
20180611_Jointopinion_DBBAG_EN.pdf
(114 KB)
20180530_PM Balaton offer_EN.pdf
(116 KB)
20180530_ 1stQEarningsRelease_EN.pdf
(142 KB)
20180529_PRSalesforce_UK_EN.pdf
(44 KB)
20180522_Telco_1Q_EN.pdf
(40 KB)
20180430_PR2017Annualresult_EN.pdf
(146 KB)
20180426 PR Balaton offer_EN.pdf
(40 KB)
20180419_Telco_AR_EN.pdf
(39 KB)
20180315_RückzahlungWSV_EN.pdf
(59 KB)
20180315_BezugspreiseWSV_EN.pdf
(45 KB)
20180228_PR_BCC_ReimbursementScotland_EN.pdf
(41 KB)
20180216 PR Closing ADR_EN.pdf
(47 KB)
20180122_2017_RevenuePre_EN.pdf
(91 KB)
2017
2017
01/30/2017 Biofrontera Launches New U.S. Website and increases sales force to Support Launch and Commercialization of Ameluz®
(101 KB)
02/08/2017 Biofrontera adds body cream to belixos® dermo-cosmetics series
(97 KB)
02/28/2017 Biofrontera to Present at Cowen and Company's 37th Annual Healthcare Conference
(49 KB)
03/13/2017 Biofrontera Reports Detailed Phase III Results for Ameluz® in Combination with Daylight-PDT
(111 KB)
04/03/2017 Notice of Annual Results 2016
(33 KB)
04/06/2017 Biofrontera Reports Full Year 2016 Financial Results
(255 KB)
05/08/2017 Notice of first quarterly report of 2017
(32 KB)
05/19/2017 Biofrontera Reports First Quarter 2017 Financial Results
(219 KB)
05/19/2017 EIB grants financing to Biofrontera
(115 KB)
05/30/2017 Biofrontera to Present at the 2017 Marcum Microcap Conference
(97 KB)
06/12/2017 Biofrontera Files Label Extension for Ameluz® in EU to include Treatment with Daylight-PDT for Actinic Keratosis
(241 KB)
08/02/2017 Ameluz® launch for Actinic Keratosis in Israel
(42 KB)
08/04/2017 Biofrontera Agrees with U.S. FDA on Ameluz® Development Plan to Treat Basal Cell Carcinoma
(121 KB)
08/09/2017 Biofrontera strengthens its U.S. sales support services
(417 KB)
08/21/2017 Advanced notice of conference calls on half-year report of 2017
(35 KB)
08/30/2017 Biofrontera to Present at the 19th Annual Rodman & Renshaw Global Investment Conference
(112 KB)
08/31/2017 Biofrontera Grows Revenues and Improves Financial Position in First Half 2017
(112 KB)
09/28/2017 Biofrontera Strengthens U.S. Team with Appointment of Jeffrey Holm as Vice President of Marketing
(38 KB)
10/09/2017 Biofrontera’s Ameluz® and BF-RhodoLED® Listed on the U.S. VA Federal Supply Schedule
(38 KB)
10/16/2017 Biofrontera to Present at the McGuire Woods 9th Annual Pharmaceutical and Medical Device Conference
(35 KB)
10/18/2017 Biofrontera achieves strong U.S. sales performance of Ameluz® in first year of commercialization
(47 KB)
11/10/2017 CMS issues new reimbursement codes for Ameluz® and for Photodynamic Therapy
(48 KB)
11/20/2017 Biofrontera Announces Conference Call to Discuss Third Quarter 2017 Financial Results
(40 KB)
11/26/2017 Biofrontera Reports Financial Results for Third Quarter and First Nine Months of 2017
(133 KB)
12/04/2017 Biofrontera to Present at the 10th Annual LD Micro Main Event
(278 KB)
12/19/2017 Biofrontera Files Investigational New Drug Application
(272 KB)
2016
2016
01/26/2016 FDA completes Biofrontera’s Ameluz® NDA mid-cycle review
(151 KB)
02/11/2016 Data from pivotal Phase III studies with BF-200 ALA: First introduction to US dermatologists as a poster and two oral presentations at the 14th South Beach Symposium
(199 KB)
03/04/2016 Biofrontera announces full results of Phase III clinical trial evaluating BF-200 ALA for treatment of basal cell carcinoma (BCC)
(207 KB)
03/31/2016 Swiss compulsory health insurance reimburses Ameluz® for treatment of actinic keratosis
(196 KB)
04/04/2016 Biofrontera Announces NDA Progress Update for BF-200 ALA
(246 KB)
04/07/2016 Notice of Annual Results 2016
(97 KB)
04/13/2016 Israel Ministry of Health Approves Biofrontera’s Ameluz® for treatment of actinic keratosis
(244 KB)
04/14/2016 Biofrontera Reports Full Year 2015 Financial Results
(201 KB)
04/28/2016 Announcement of adjustment of the option price of warrants
(252 KB)
05/11/2016 Biofrontera Announces U.S. FDA Approval of Ameluz® and Activating BF-RhodoLED® Device for Treatment of Actinic Keratosis
(253 KB)
05/23/2016 Notice of quarterly report of 2016
(98 KB)
05/25/2016 Biofrontera Reports First Quarter 2016 Financial Results and Business Update
(268 KB)
06/02/2016 Biofrontera Announces Appointment of Four New Supervisory Board Members
(251 KB)
06/23/2016 Biofrontera Progresses with Expansion of U.S. Subsidiary with Key Personnel Hires
(198 KB)
06/30/2016 Biofrontera Initiates Phase III Trial of Ameluz® in Combination with Daylight-PDT
(301 KB)
07/08/2016 Biofrontera Expands belixos® Dermo-Cosmetics Product Line with belixos® To Go
(292 KB)
07/25/2016 Biofrontera to Present at the Canaccord Genuity Annual Growth Conference
(96 KB)
08/25/2016 Biofrontera Accelerates Production of BF-RhodoLED® Lamps to Prepare for U.S. Commercial Launch
(41 KB)
08/25/2016 Notice of half-year report of 2016
(33 KB)
08/29/2016 Biofrontera to Present at the 18th Annual Rodman & Renshaw Global Investment Conference
(33 KB)
08/30/2016 Biofrontera Reports Financial Results and Business Update for Second Quarter and First Half 2016
(90 KB)
09/16/2016 Biofrontera Receives Label Expansion for Ameluz® in Europe to Include Field Cancerization
(179 KB)
09/19/2016 Biofrontera Completes Patient Recruitment of Phase III Trial of Ameluz® in Combination with Daylight-PDT
(79 KB)
10/07/2016 Biofrontera to Present at the Dawson James Securities 2nd Annual Growth Stock Conference
(106 KB)
10/18/2016 Biofrontera Initiates U.S. Commercial Launch of Ameluz® for Actinic Keratosis
(208 KB)
10/20/2016 Biofrontera Announces 12-Month Follow-Up Results of Phase III Trial Evaluating Ameluz® for Basal Cell Carcinoma
(114 KB)
07/28/2016 Biofrontera Receives Favourable CHMP Assessment for Field-Directed Therapy and Files BCC Application
(54 KB)
11/24/2016 Notice of 3rd quarterly report 2016
(33 KB)
11/28/2016 Biofrontera Reports Financial Results and Business Update for Third Quarter and First Nine Months 2016
(90 KB)
11/28/2016 European Commission provides unlimited approval for Ameluz®
(72 KB)
11/30/2016 Biofrontera to Present at the 9th Annual LD Micro Main Event
(33 KB)
12/20/2016 European Medicines Agency recommends indication expansion of Ameluz® for treatment of basal cell carcinoma (BCC)
(136 KB)
2015
2015
01/22/2015 Biofrontera AG selects designated sponsor in Germany
(85 KB)
01/26/2015 Biofrontera prepares market launch in Belgium for its non-melanoma skin cancer drug Ameluz®
(100 KB)
03/24/2015 Biofrontera starts Sales and Marketing of Ameluz® in Spain
(156 KB)
03/29/2015 Notice of Annual Results 2014
(85 KB)
04/08/2015 Biofrontera stabilizes shareholder structure
(100 KB)
04/09/2015 Biofrontera significantly increases its turnover in Germany in 2014
(107 KB)
04/16/2015 Biofrontera starts with robust growth into the new year
(110 KB)
04/19/2015 Biofrontera establishes subsidiary in the US
(145 KB)
05/06/2015 Biofrontera delivers excellent results from the Phase III study for field therapy of actinic keratosis for publication
(108 KB)
05/22/2015 Notice of First Quarter Results 2015
(75 KB)
05/29/2015 Biofrontera delivers strong performance for Q1 2015
(113 KB)
06/22/2015 Biofrontera completes final steps ahead of FDA New Drug Application in the USA
(111 KB)
07/13/2015 Biofrontera submits New Drug Application for Ameluz® to FDA
(169 KB)
07/16/2015 Biofrontera launches ‘Belixos® Protect’, a daily skincare product for sun-damaged skin
(140 KB)
07/22/2015 Biofrontera appoints Christoph Dünwald as Chief Commercial Officer
(111 KB)
08/07/2015 Biofrontera AG Notice of First Half Year Results 2015
(86 KB)
08/13/2015 Biofrontera progresses well in first half year 2015
(107 KB)
31/08/2015 Biofrontera - Result of Annual General Meeting
(94 KB)
09/21/2015 Excellent long-term outcome with field treatment of actinic keratosis with Ameluz®
(92 KB)
10/01/2015 FDA determines May 10, 2016 as PDUFA* date for Ameluz®
(133 KB)
11/11/2015 Biofrontera's business operations on track
(128 KB)
11/12/2015 Biofrontera AG Notice of Third Quarter Results 2015
(76 KB)
11/19/2015 Biofrontera reports final patient visit in phase III trial for basal cell carcinoma
(78 KB)
11/20/2015 Q3 Results well on track
(129 KB)
12/07/2015 Swissmedic grants marketing approval for Ameluz® in Switzerland
(79 KB)
12/13/2015 FDA grants small business waiver
(97 KB)
2014
2014
02/21/2014 Belixos® - nature‘s best to nurture your skin! Social media campaign started02/21/2014 Belixos® - nature‘s best to nurture your skin! Social media campaign started
(207 KB)
02/27/2014 Biofrontera expands the Belixos® cosmeceutical product series
(190 KB)
03/26/2014 Biofrontera publishes financial report 2013
(217 KB)
05/19/2014 Biofrontera AG publishes 1st quarter 2014 interim report
(218 KB)
07/02/2014 PDT with Ameluz® is the most efficacious treatment option for actinic keratosis
(78 KB)
08/06/2014 First Ameluz® sales in Central Eastern European region
(127 KB)
08/11/2014 Ameluz® has passed first stage in approval process in Israel
(89 KB)
08/18/2014 Belixos® now available through Amazon in Germany and UK
(123 KB)
08/21/2014 Pre-NDA meeting scheduled with FDA for the approval of Ameluz® and BF-RhodoLED®
(133 KB)
08/29/2014 Half Year Results: Progress in business operations
(256 KB)
11/11/2014 Biofrontera AG hosts conference call on 13 November 2014 to present results of the 3rd quarter 2014
(100 KB)
11/13/2014 Biofrontera publishes report on the third quarter of 2014
(113 KB)
11/25/2014 Further progress in international approval processes of Biofrontera’s Ameluz®
(151 KB)
12/05/2014 Biofrontera launches new addition Belixos® Gel to its derma-cosmetic line
(97 KB)
2013
2013
01/08/2013 Biofrontera receives positive EMA opinion on extended storage conditions for Ameluz®
(91 KB)
03/12/2013 Biofrontera explains corporate strategy and clinical development program in telephone conference
(85 KB)
03/25/2013 Maschmeyer increases share holding in Biofrontera AG
(79 KB)
04/11/ 2013 Biofrontera AG to host conference call on 15 April 2013 to present results of the fiscal year 2012
(140 KB)
04/15/2013 Biofrontera AG publishes financial results for 2012
(101 KB)
05/17/2013 Biofrontera publishes 1st quarter 2013 interim report
(226 KB)
06/04/2013 Biofrontera AG appoints Thomas Schaffer as CFO
(89 KB)
06/10/2013 Biofrontera AG with new Corporate Website
(81 KB)
08/01/2013 Biofrontera AG appoints M.M.Warburg & CO as new Designated Sponsor
(164 KB)
08/23/2013 Biofrontera AG reports half-year financial results for 2013
(79 KB)
09/06/2013 Biofrontera announces brokerage agreement and research coverage with finnCap
(79 KB)
09/20/2013 Actinic keratosis, most efficiently treated by Ameluz®, recognized as occupational disease
(169 KB)
10/14/2013 Patient recruitment started in phase III study for field-therapy of actinic keratosis
(89 KB)
10/21/2013 Allergan launches Ameluz® in Spain
(101 KB)
11/08/2013 Biofrontera publishes interim report for the 3rd quarter of 2013
(90 KB)
12/12/2013 All Wales Medicine Strategy Group recommends the use of Ameluz®
(88 KB)